#ASH20: Bain execs step in to position a somewhat battered and bruised Syros with a new clinical candidate and enough money to charge ahead

Syros $SYRS CEO Nancy Simonian had more than data to discuss during the virtual ASH sessions this weekend.

On top of a new cut of the data for their lead cancer drug, SY-1425, a trio of Bain execs has stepped in to set up a major new infusion of funds along with a new product acquisition aimed at beefing up the pipeline as they shoot for the proverbial “fully integrated” status of a commercial player.